deemed a benign consequence of ageing, is also now known to confer a 40% increase in the risk of death and a 66% increase in the risk of CV death, independent of age and CV risk factors 7 .
This lesion, which appears to track with vascular disease risk factors, has led to a misconception that aortic sclerosis and vascular atherosclerosis represent the same disease. Although there is significant overlap in the early initiating lesion and certain shared risk factors [8] [9] [10] [11] , the available evidence indicates major differences in the underlying pathophysiology of these two diseases.
First, histopathological evidence demonstrates a more prominent early mineralization phase and a paucity of smooth muscle cells in aortic sclerosis, as compared to vascular atherosclerotic lesions 9 . Second, calcification pathways appear to predominate early in valve disease and appear to be independent of the atherosclerotic process as opposed to vascular disease where calcification develops much later and in parallel with atherosclerosis 12 . Third, among individuals undergoing AV replacement for (non-congenital) AS, only 40% have significant CAD requiring bypass 13 suggesting unique pathological processes. Fourth, lipid lowering agents, which have been remarkably effective for preventing atherosclerosis have not demonstrated any benefit in randomized trials for advanced AV disease, in older patient populations, highlighting the major differences in pathophysiology and treatment of these diseases [14] [15] [16] .
Lp(a) is associated with Calcific Aortic Valve Disease
A major limitation in developing treatments for CAVD stems in large part from our poor understanding of the mediators and causes of this disease. Seminal early pathologic studies performed by Otto et al. clearly demonstrated the importance of lipids in the early initiating lesion of CAVD. They demonstrated that the early sclerotic lesions of aortic valves were characterized by lipid pools that were absent in adjacent normal valve tissue, implicating lipids in the pathological process 9 . In addition, these lipids were likely derived from plasma, as plasma by guest, on October 14, 2017 www.jlr.org
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carrier molecules for cholesterol (apoB and apo [a] ) were also present in these pools 17 . These cholesterol particles co-localized with early foci of calcification in valve tissue providing the first evidence that blood-borne cholesterol, either from LDL and/or Lp(a), were intimately involved in the early calcification of the aortic valve.
Subsequent epidemiologic studies (summarized in the These results were also independently confirmed in the Copenhagen City Heart Study in which the rs10455872 was associated with both incident aortic stenosis and aortic valve replacement 21 .
In both cohorts, the association persisted after adjustment for several risk factors and after provided further independent replication in the 17,553 participants of the prospective EPICNorfolk study 27 . Compared to individuals with no copies of the G risk allele (i.e. Lp(a) increasing), individuals heterozygous and homozygous for the G allele had a hazard a hazard ratio of 1.78 (95% CI 1.11-2.87) and 4.83 (95% CI 1.77-13.20), respectively, for incident aortic stenosis. They also provided replication in a case-control study demonstrating that carriers of the G allele had a 57% increase in the odds of AS, as compared to those without the G allele. years of age) than in older participants indicating an important age x Lp(a) interaction (p= 0.04).
In multivariable models, Lp(a) > 58.5 mg/dL was associated with a 2.6 fold increase in the odds of being a rapid progressor, as defined by an annualized change in maximum aortic velocity > 0.2/ms/year. Importantly, in those ≤57 years, the odds ratio for rapid progression was 4.9 (95% CI 1.8-3.7). These results demonstrate robust evidence in support of elevated Lp(a) as a marker of rapid progression of aortic stenosis, especially in younger individuals, and provide strong evidence to target Lp(a) lowering to this group of patients.
Potential mechanisms of Lp(a)-mediated calcific aortic valve disease
Due to the recent discoveries linking LPA variants with aortic valve disease, there are currently limited molecular and animal studies exploring the mechanisms underlying this association, which represents an important knowledge gap that will need to be addressed in the near future. Nonetheless, Lp(a) has several important properties that could promote AV disease has been hypothesized that a physiologic role for Lp(a) may be to bind and transport proatherogenic OxPL in plasma, targeting them for removal from the circulation. 34 Although OxPL have been found on several plasma proteins, including LDL and plasminogen, Lp(a) carries the largest proportion (~85%) of circulating OxPL on plasma lipoproteins 35 . Lp(a) levels are highly correlated with OxPL/apoB levels (r = 0.85), but this correlation is not consistent for all Lp(a) particles, with highest correlations observed among the smallest, most atherogenic Lp(a) particles [36] [37] [38] . OxPL appear to be "danger-associated molecular patterns" which are potent stimulators of innate immunity by interacting with various pattern recognition receptors 12, 39 40 . Based on these properties, Lp(a) may mediate AV disease by binding to areas of denuded valvular tissue, leading to excessive deposition of Lp(a), thus delivering apoB, cholesterol and highly atherogenic, pro-calcifying OxPL to the leaflet surface culminating in a pro-inflammatary and pro-calcifying cascade at the valve leaflets (see Figure 2 ). This process is likely magnified several fold at the AV and at other areas of high hemodynamic stress (i.e. vascular branch points), which may also explain the higher predilection of calcification at these sites as compared to the remainder of the cardiovascular system.
Future Directions: Can Aortic Stenosis be prevented by Lp(a) targeted therapy?
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A preventative treatment for CAVD could markedly improve quality of life for older patients, limit the number of valve replacements with a significant cost savings for our health care system and reduce death and disability in this vulnerable age group. Although the failure of previous randomized trials to prevent aortic stenosis using lipid-lowering therapies 15, 16, 47 has dampened enthusiasm for prevention, CAVD has attractive characteristics for this approach: an easily identified sub-clinical phase that characterizes at risk individuals; a slow regulated process that begins many years prior to clinical manifestations and provides a time window for intervention; and, at the very least, a partially shared pathophysiology with atherosclerosis, a highly preventable disease, that can be successfully managed with pharmacotherapy.
To date, the only major strategy for the prevention of CAVD has been the lowering of low-density lipoprotein using statins (and ezetimibe in one trial). Four randomized trials of LDL lowering have been completed and the results have been overwhelmingly negative -statins by lowering LDL do not appreciably reduce the progression of aortic valve disease 15, 16, 47 . These results were confirmed by a recent meta-analysis, 53 which reported that despite marked lowering of LDL (35-55%) for more than 2 years (2.5-4 years in the different trials) in these trials, there was no evidence for a reduction in echocardiographic parameters in aortic stenosis progression or in clinical outcomes (i.e. death, aortic valve replacement, hospitalization for AS etc.).
Nonetheless, these trials had major limitations. They were, in large part, performed late in the disease process, could not be performed in individuals with an indication for statin therapy (i.e. many individuals with high cholesterol could not be ethically randomized to placebo) and used statin therapy as the preferred treatment approach, despite some evidence that statins in advanced vascular disease could promote calcification (which may stabilize vascular lesions but worsen AS) 13 . Although the relevance of Lp(a) was not known at the time of these trials, statins also do In summary, the recent identification of genetic variants in LPA as being strongly associated with calcific aortic valve disease, and the Mendelian randomization studies demonstrating that this genetic association is mediated by circulating Lp(a), as well as our increased understanding of the mechanisms of Lp(a) and their potential role in atherogenesis and cardiovascular calcification, has reignited intense interest in Lp(a) in general, but also as a specific therapeutic target for calcific aortic valve disease. It is hoped that lowering of Lp(a) will demonstrate reduced progression of aortic valve disease and that targeted therapies directed at Lp(a) will become the preferred treatment for aortic valve disease in at risk individuals with high Lp(a) and, ultimately, will reduce the need for valve replacement and the costs and complications of CAVD. C. Lp(a) binds avidly to areas of endothelial injury (Neilsen et al. Circ Research 1998) 29 . The aortic valves (in blue) are particularly susceptible to denudation (denoted by X in the figure) due to hemodynamic stress.
D.
Deposition of Lp(a) leads to delivery of oxPL , a known promoter of osteoblastic differentiation (and calcification) (Parhami et al. ATVB 1997) 48 .
